Marie Saghaeian Jazi

Dr. Marie Saghaeian Jazi


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
ASAlireza Shahryari
Alireza Shahryari
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
NSNader M. Samaei
Nader M. Samaei
SMSeyed Javad Mowla
Seyed Javad Mowla
SOX2 overlapping transcript (SOX2OT) is a long non-coding RNA (lncRNA) which harbors one of the major regulators of pluripotency, SOX2 gene, in its intronic region. SOX2OT gene is mapped to human chromosome 3q26.3 (Chr3q26.3) locus and is extended in a high conserved region of over 700 kb. Little is known about the exact role of SOX2OT; however, recent studies have demonstrated a positive role for it in transcription regulation of SOX2 gene. Similar to SOX2, SOX2OT is highly expressed in embryonic stem cells and down-regulated upon the induction of differentiation. SOX2OT is dynamically regulated during the embryogenesis of vertebrates, and delimited to the brain in adult mice and human. Recently, the disregulation of SOX2OT expression and its concomitant expression with SOX2 have become highlighted in some somatic cancers including esophageal squamous cell carcinoma, lung squamous cell carcinoma, and breast cancer. Interestingly, SOX2OT is differentially spliced into multiple mRNA-like transcripts in stem and cancer cells. In this review, we are describing the structural and functional features of SOX2OT, with an emphasis on its expression signature, its splicing patterns and its critical function in the regulation of SOX2 expression during development and tumorigenesis.

4 February 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
NSNader Mansour Samaei
Nader Mansour Samaei
MGMostafa Ghanei
Mostafa Ghanei
MSMohammad Behgam Shadmehr
Mohammad Behgam Shadmehr
SMSeyed Javad Mowla
Seyed Javad Mowla

24 December 2015 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
NSNader Mansour Samaei
Nader Mansour Samaei
MGMostafa Ghanei
Mostafa Ghanei
MSMohammad Behgam Shadmehr
Mohammad Behgam Shadmehr
SMSeyed Javad Mowla
Seyed Javad Mowla

Verified
Journal Article
Open access
PDF file
SZSareh Zhand
Sareh Zhand
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
Saeed MohammadiSaeed Mohammadi
Saeed Mohammadi
RRRoozbeh Tarighati Rasekhi
Roozbeh Tarighati Rasekhi
GRGhassem Rostamian
Ghassem Rostamian
Mark William DouglasMark William Douglas
Mark William Douglas
The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.

1 May 2010 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SSSara Salmanian
Sara Salmanian
SNS. Mahmoud A. Najafi
S. Mahmoud A. Najafi
MRMaryam Rafipour
Maryam Rafipour
MAMaryam Rezaei Arjomand
Maryam Rezaei Arjomand
HSHamideh Shahheydari
Hamideh Shahheydari
TMTayebeh Minaei
Tayebeh Minaei

28 June 2023 in Primary Care Diabetes
Verified
Journal Article
Closed access
MSMahdieh Safarzad
Mahdieh Safarzad
MJMarie Saghaeian Jazi
Marie Saghaeian Jazi
MKMohammadreza Kiaei
Mohammadreza Kiaei
JAJahanbakhsh Asadi
Jahanbakhsh Asadi